Navigation Links
Teikoku Pharma USA Acquires Travanti Pharma Inc.
Date:5/8/2009

SAN JOSE, Calif., May 8 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc., a privately held corporation that designs, develops and markets innovative drug delivery platforms that improve the safety, compliance, effectiveness and ease of administration of medications delivered to the body.

The Company has developed a proprietary Wearable Electronic Disposable Drug delivery technology (WEDD(R)) Platform. WEDD is an innovative electronic transdermal (iontophoretic) drug delivery system that is totally self-contained, single-use, portable and disposable. The company has a number of ready to partner clinical projects focused on improving the delivery of therapeutic medications.

The acquisition is part of Teikoku's core strategy to develop transdermal pharmaceutical products by applying drug delivery technology to make administration of medicines safer and/or more effective, more controllable, and in some cases eliminating the need for injection.

"The acquisition of Travanti Pharma broadens Teikoku's Transdermal delivery capabilities and enhances Teikoku pipelines in the areas of pain and CNS," said Masahisa Kitagawa, President and CEO.

"We are very pleased to join forces with Teikoku, a company that understands our business well and has the capabilities to help move several excellent products based upon Travanti's WEDD technology into the marketplace," commented Robert Cohen, President & CEO of Travanti Pharma. "It is gratifying to complete a transaction that benefits Teikoku, as well as Travanti's shareholders and employees."

About Teikoku

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain Management and CNS. Teikoku's main product is Lidoderm(R) (Lidocaine 5% Patch) for PHN, in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

Teikoku's commitment is to expand transdermal technologies for the benefit of patients and partners. For more information, please visit www.teikokuusa.com


'/>"/>
SOURCE Teikoku Pharma USA Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: